Thanks for sharing. I don’t know about NEU’s drug usage but for FSGS the patients are expected to continue use for the rest of their lives so recurring revenue for a long time even if we don’t have ODD pricing but as long as patent extends the pricing should be quite good.
Also Nina has said before that FSGS is not identified early enough or misdiagnosed. Now imagine the same happening world over. If these patients also are added to the funnel the TAM gets bigger.
Also NEU’s Daybue has only one indication - Rett Syndrome, while their next trial drug NNZ-5591 targets multiple indications. Our DMX-200 already can target multiple indications.
Many things to consider. AIMO.
DXB - Research & Valuation, page-223
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
43.5¢ |
Change
0.045(11.5%) |
Mkt cap ! $234.0M | |||
| Open | High | Low | Value | Volume |
| 40.5¢ | 44.0¢ | 40.0¢ | $2.225M | 5.387M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 11627 | 43.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 43.5¢ | 126213 | 4 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |